FTLD-Tau vs FTLD-TDP
All participants
24 FTLD-Tau vs 25 FTLD-TDP
No copathology
20 FTLD-Tau vs 18 FTLD-TDP
AUC (95% CI)Best-fit cut-offSe (%)Sp (%)AUC (95% CI)Best-fit cut-offSe (%)Sp (%)
sAPPβ0.58 (0.42 to 0.74)393 ng/mL85270.58 (0.39 to 0.76)364 ng/mL8920
YKL-400.67 (0.51 to 0.83)336 ng/mL85160.79 (0.63 to 0.94)328 ng/mL8930
sAPPβ:YKL-40 ratio0.67 (0.51 to 0.82)1.5186390.71 (0.54 to 0.88)1.288935
  • Best-fit cut-off values were obtained for sAPPβ, YKL-40 and the sAPPβ:YKL-40. Specificity was optimised for a sensitivity level of at least 85%.

  • AD, Alzheimer’s disease; AUC, area under the curve; CN, cognitively normal control; FTLD, frontotemporal lobar degeneration; Se, sensitivity; Sp, specificity; sAPPβ, soluble β fragment of amyloid precursor protein.